Weight Loss: Weekly jab makes the body feel full and causes a 50 lb drop

The participants in the study lost an average of 22.5 percent of their body weight. This is more than double the normal effectiveness of such treatments and could offer an alternative to surgery for people with obesity.

Elderly overweight man measuring his weight on bathroom scales
A new weight-loss injection resulted in study participants losing 24 kg

A weight loss treatment that causes your body to feel full has achieved an average weight loss of 24 kg in phase three clinical trials. For the obese participants, this equated to losing almost a quarter of their weight.

Obesity experts hope this treatment, in which the patient gives a single weekly injection at home, could be an alternative to expensive and invasive bariatric surgeries like gastric bands and bypasses.

In the third phase of the study, over 2,500 people in nine countries, each weighing an average of 105 kilograms, were given weekly injections of various doses of ‘Tirzepatid’ or a placebo for 72 weeks. Participants were unaware of which ones they were taking.

Want the latest health news straight to your inbox? Login here

The drug is manufactured by pharmaceutical giant Eli Lilly



Those on the highest doses experienced the greatest weight loss over the 72 weeks, during which participants also had to maintain a moderate diet and exercise regimen.

Those in the study’s control group, who received a placebo, saw an average weight loss of just 2kg, giving a boost to the drug’s maker, pharmaceutical giant Eli Lilly.

Jeff Emmick Ph.D., vice president of product development at Lilly, said: “Tirzepatide is the first investigational drug to produce an average of more than 20 percent weight loss in a phase 3 study, which reinforces our confidence in its potential to help people living with obesity.”

Tirzepide works by making synthetic copies of the hormones your stomach produces to tell your brain that you are full. Similar but less effective drugs like Semaglutide have recently entered the weight loss market and have been described as the “holy grail” of obesity treatment.

When Eli Lilly’s SURMOUNT-1 study began, the study’s 2,539 participants weighed 231 pounds and had an average BMI of 38. Most participants did not qualify for bariatric surgery, which included people with a BMI over 40 or those with a BMI of 35 to 40 are reserved who also suffer from sleep apnea or type 2 diabetes.

“Tirzepatide resulted in an impressive reduction in body weight in SURMOUNT-1, which could represent an important step forward in helping the patient-physician partnership manage this complex disease,” said Louis Aronne, director of the Comprehensive Weight Control Center New York’s Cornell Medical Center.

At the end of the study, the BMIs of those receiving the higher doses of tirzepatide dropped to just 30 – putting them in the “normal” range on the BMI weight scale, although they were still overweight.

Because obesity is a chronic condition, these injections could be a lifelong treatment for many, but far more manageable than the diseases and difficulties associated with obesity; These include musculoskeletal complications, type 2 diabetes, heart disease and at least 13 types of cancer.

This new treatment is not without side effects, including constipation, diarrhea, nausea, and vomiting in mild to moderate cases. Although the study scientists noted that these “side effects” were less than with other similar treatments.

Continue reading

Continue reading Weight Loss: Weekly jab makes the body feel full and causes a 50 lb drop

Fry Electronics Team

Fry is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button